BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Approves EffRx's BINOSTO®, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution


3/14/2012 9:34:24 AM

FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA today announced that the United States Food and Drug Administration (FDA) has approved BINOSTO® (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO® will be commercially available in the United States in the third quarter of 2012.

Christer Rosén, Chairman & CEO of EffRx states: “We are very pleased to receive this approval from the FDA. BINOSTO® is a breakthrough innovation for the treatment of osteoporosis, offering those patients that have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy to swallow buffered solution.”

Osteoporosis affects more than 200 million people in the 7 major markets and the global market is estimated to be USD10 billion and growing, especially in the emerging markets. BINOSTO® is an innovative treatment option that can assure physicians that they are providing a proven efficacious therapy for those patients who have difficulty with tablets. A Harris Interactive Poll concluded that up to 40% of American adults have difficulties with swallowing tablets.

About BINOSTO®:

BINOSTO® is a once weekly, strawberry flavored effervescent tablet containing alendronate 70mg that rapidly dissolves in half a glass (4oz) of plain room temperature water to make a buffered solution. BINOSTO® is available in packs of 4 and 12 tablets.

BINOSTO® was developed by EffRx based on an agreement with Merck & Co, Inc. granting EffRx the worldwide rights to all effervescent and related patents of FOSAMAX® (alendronate). Patents have been granted to EffRx providing exclusivity for BINOSTO® through February 2023. Additional patents are pending.

About EffRx:

EffRx Pharmaceuticals SA is a drug delivery company based in Freienbach, Switzerland. EffRx specializes in improving existing high volume pharmaceutical products by utilizing its novel techniques in different effervescent executions. The primary focus of EffRx is in metabolic bone disease, oncology supportive care, pediatric medications and support to larger companies in Life Cycle Management.

EffRx has a licensing agreement with Nycomed, a Takeda Company, for development, manufacturing and commercialization of EffRx patented effervescent alendronate for the treatment of osteoporosis in all territories in the world except USA, Canada and Japan.

Contacts

EffRx Pharmaceuticals SA

Christer Rosén

Chairman & CEO

+41 799636600

crosen@effrx.com

or

Marshall Hayward

Chief Scientific Officer

+41 799636604

mhayward@effrx.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->